55745-97-6

Usage

Uses

Used in Pharmaceutical Industry:
Chroman-6-carbaldehyde is used as an intermediate compound for the synthesis of various pharmaceutical products. Its presence in the molecular structure of some drugs allows for the development of new medications with potential therapeutic applications.
Used in Agrochemical Industry:
Chroman-6-carbaldehyde is used as an intermediate compound in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties contribute to the effectiveness of these products in controlling pests and weeds in agricultural settings.
Used in Flavor and Fragrance Industry:
Chroman-6-carbaldehyde is used as a flavoring agent and a fragrance ingredient in the production of perfumes, cosmetics, and other scented products. Its aromatic properties provide a unique and pleasant scent that can be incorporated into various formulations.

Upstream product

• 493-08-3 chromane 
• 74-90-8 hydrogen cyanide 
• 68-12-2 N,N-dimethyl-formamide 
• 254-04-6 2H-chromene 
• 91-64-5 coumarin 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 67856-45-5 6-iodo-chroman 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 14864-24-5 (Z)-2-(3-hydroxyprop-1-en-1-yl)phenol 
• 1481-92-1 2-(3-hydroxypropyl)phenol 

Downstream Products

• 101352-19-6 chroman-6-carbaldehyde-(2,4-dinitro-phenylhydrazone) 
• 3722-74-5 3,4-Dihydro-6-methyl-2H-1-benzopyran 
• 81257-93-4 1,7,8,9-Tetrahydro-pyrano[2,3-g]indole 
• 81257-90-1 acide tetrahydro-1,7,8,9-pyranno<2,3-g>indolecarboxylique-2 
• 83868-31-9 Dimethyl-(1,7,8,9-tetrahydro-pyrano[2,3-g]indol-3-ylmethyl)-amine; compound with picric acid 
• 1403381-88-3 (2E)-2-(3,4-dihydro-2H-1-benzopyran-6-ylmethylidene)cyclohexan-1-one 
• 1403381-89-4 N-[(2E)-2-(3,4-dihydro-2H-1-benzopyran-6-ylmethylidene)cyclohexylidene]hydroxylamine 
• 1418718-38-3 C₃₁H₃₃FN₂O₄ 
• 1418713-79-7 2-(tert-butoxy)-2-(4-(chroman-6-yl)-1-(4-fluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)acetic acid 
• 1418718-41-8 methyl 4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylate 
• 1418718-44-1 (4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methanol 
• 1418718-47-4 4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde 
• 1418718-53-2 C₂₉H₂₉F₂N₃O₂Si 
• 1418718-50-9 methyl 2-(4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-hydroxyacetate 

Relevant academic research and scientific papers

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).

Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands

A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.